8-K: ANI Pharmaceuticals' ILUVIEN NEW DAY Study Misses Primary Endpoint in Key Population, Shows Mixed Results for Early DME

ANI Pharmaceuticals announced mixed results from its NEW DAY Study for ILUVIEN in early diabetic macular edema, failing to meet its primary endpoint in the intent-to-treat population but showing benefits in a per-protocol analysis and extended re-treatment intervals.

Summary

• The NEW DAY Study evaluated ILUVIEN as baseline therapy for patients with early Diabetic Macular Edema (DME), comparing it against aflibercept.
• The study included 306 patients randomized 1:1 to receive either an ILUVIEN implant or aflibercept (2 mg) injections.
• The primary endpoint, mean total number of supplemental aflibercept injections needed in the Intent-to-Treat (ITT) population from baseline to Week 72, was not met, with ILUVIEN patients requiring 2.4 injections compared to 2.5 for aflibercept (p=0.756).
• In a post-hoc Per-Protocol (PP) population analysis, ILUVIEN demonstrated a statistically significant reduction in supplemental aflibercept injections, with 1.8 injections for ILUVIEN versus 2.5 for aflibercept (p=0.029).
• The total number of injections needed over the course of the study in the PP population was 2.8 for ILUVIEN (including the initial implant) compared to 7.5 for aflibercept.
• ILUVIEN showed a statistically significant increase in the mean time to first supplemental therapy from the last injection in the induction phase, with 185.4 days for ILUVIEN versus 132.8 days for aflibercept in the ITT population (p<0.001).
• Visual acuity and anatomic changes (Central Subfield Thickness) demonstrated non-inferiority between both arms, though the prespecified non-inferiority margin of 4 ETDRS letters for BCVA was not met in the ITT population (p=0.080 at month 18).
• Approximately one-third of patients in both arms did not require any supplemental injections during the study (32.5% for ILUVIEN vs. 30.3% for aflibercept in ITT, p=0.678).
• The safety profile showed higher rates of treatment-related adverse events for ILUVIEN (40.9%) compared to aflibercept (3.3%).
• Ocular adverse events, specifically cataract (29.9% for ILUVIEN vs. 0.7% for aflibercept) and increased intraocular pressure (7.8% for ILUVIEN vs. 0.7% for aflibercept), were more frequent in the ILUVIEN arm.
• No retinal detachments or endophthalmitis were reported in the ILUVIEN arm.

Sentiment

Score: 4

Explanation: The sentiment is mixed to slightly negative. While the study showed positive outcomes in the per-protocol analysis and a significantly longer time to re-treatment, the failure to meet the primary endpoint in the Intent-to-Treat population is a significant setback. Additionally, the higher incidence of ocular adverse events, particularly cataracts and increased intraocular pressure, presents a notable safety concern that could impact market adoption and physician preference.

Positives

• ILUVIEN demonstrated a statistically significant reduction in the mean number of supplemental aflibercept injections in the Per-Protocol (PP) population (1.8 vs. 2.5 injections, p=0.029).
• Patients treated with ILUVIEN required a lower total number of aflibercept injections over the study duration (2.8 vs. 7.5 injections) in the PP population.
• ILUVIEN significantly extended the mean time to first supplemental therapy (185.4 days vs. 132.8 days, p<0.001) in the ITT population, indicating a longer duration of effect.
• Visual acuity and anatomic changes (Central Subfield Thickness) were comparable between ILUVIEN and aflibercept arms, demonstrating non-inferiority in these aspects.
• Approximately one-third of patients in both treatment arms did not require any supplemental injections during the study period.
• No cases of retinal detachment or endophthalmitis were observed in the ILUVIEN treatment arm.

Negatives

• The primary endpoint, mean number of supplemental aflibercept injections in the Intent-to-Treat (ITT) population, was not met (2.4 vs. 2.5 injections, p=0.756), indicating no statistically significant difference in the broader patient group.
• ILUVIEN was associated with a significantly higher rate of treatment-related adverse events (40.9%) compared to aflibercept (3.3%).
• A higher incidence of cataracts was observed in the ILUVIEN arm (29.9%) compared to the aflibercept arm (0.7%).
• Increased intraocular pressure (IOP) events were more frequent with ILUVIEN (15.6%) than with aflibercept (3.3%).
• A higher percentage of ILUVIEN patients required IOP-lowering laser therapy or incisional surgery (4.5%) compared to aflibercept patients (1.3%).
• The prespecified non-inferiority margin for mean change from baseline in BCVA score was not met in the ITT population (p=0.080 at month 18).

Risks

• Ability of approved products, including Cortrophin Gel, ILUVIEN, and YUTIQ, to achieve commercialization at levels of market acceptance that will continue to allow profitability.
• Ability to complete or achieve intended benefits of acquisitions and investments, including the acquisition of Alimera, in a timely manner or at all.
• Limitation of cash flow due to indebtedness and liabilities incurred from the acquisition of Alimera.
• Risks that acquisitions and investments, including the acquisition of Alimera, could disrupt business and harm financial position and operating results.
• Delays and disruptions in production of approved products, increased costs, and potential loss of revenues if supplier changes are needed due to limited number of suppliers for raw materials, active pharmaceutical ingredients, excipients, and other materials.
• Delays and disruptions in production of approved products due to reliance on single-source third-party contract manufacturing supply for certain key products, including Cortrophin Gel, ILUVIEN, and YUTIQ.
• Delays or failure in obtaining and maintaining approvals by the FDA of products sold.
• Changes in policy or actions by the FDA, United States Drug Enforcement Administration, and other regulatory agencies, including drug recalls, regulatory approvals, facility inspections, and potential enforcement actions.
• Risks with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies from domestic and overseas sources due to supply chain disruptions or other reasons, including increased costs due to tariffs.
• Ability of manufacturing partners to meet product demands and timelines.
• Impact of changes or fluctuations in exchange rates.
• Ability to develop, license or acquire, and commercialize new products.
• Obligations in agreements under which rights to products or technology are licensed, developed, or commercialized from third parties, and ability to maintain such licenses.
• Level of competition faced and legal, regulatory, and/or legislative strategies employed by competitors to prevent or delay competition from generic alternatives to branded products.
• Ability to protect intellectual property rights.
• Impact of legislative or regulatory reform on pricing for pharmaceutical products.
• Impact of any litigation to which the company is, or may become, a party.
• Ability of the company, its suppliers, development partners, and manufacturing partners to comply with laws, regulations, and standards governing or affecting the pharmaceutical and biotechnology industries.
• Ability to maintain the services of key executives and other personnel.
• General business and economic conditions, such as inflationary pressures, geopolitical conditions (e.g., Russia-Ukraine conflict, Middle East conflict, Red Sea attacks), and effects and duration of public health emergencies.
• Increased risk of cataracts and elevated intraocular pressure requiring intervention with ILUVIEN treatment.

Future Outlook

The company's future outlook includes the continued commercialization of approved products like Cortrophin Gel, ILUVIEN, and YUTIQ, with an emphasis on achieving market acceptance levels that ensure profitability. There is also a focus on the ability to complete and integrate acquisitions, develop, license, or acquire new products, and manage supply chain and regulatory challenges.

Management Comments

• Nikhil Lalwani, President and Chief Executive Officer, participated in the conference call to discuss the NEW DAY Study results.
• Christopher Mutz, Senior Vice President and Head of Rare Disease, provided insights on ILUVIEN and DME treatment background.
• Mary Pao, MD, PhD, Chief Medical Officer of Rare Disease, presented the NEW DAY Study overview and results.
• Michael A. Singer, MD, from Medical Center Ophthalmology Associates and University of Texas Health Science Center, San Antonio, TX, also contributed to the discussion.

Industry Context

Diabetic Macular Edema (DME) is a multifactorial disease where inflammation and angiogenesis contribute to the breakdown of the blood-retina barrier. The most common pharmacologic treatments include anti-VEGF agents and corticosteroids. Corticosteroids, like ILUVIEN, are often the treatment of choice for DME patients not well served by anti-VEGF therapy, especially given that incomplete response or resistance to anti-VEGF can be attributed to multiple causes including inflammation. ILUVIEN offers a sustained, controlled drug release for up to 36 months, addressing the burden of frequent injections associated with other treatments.

Comparison to Industry Standards

• The NEW DAY Study directly compared ILUVIEN to aflibercept (a common anti-VEGF agent like Eylea) in patients with early DME.
• While ILUVIEN did not show a statistically significant reduction in supplemental injections in the overall ITT population compared to aflibercept (2.4 vs. 2.5 injections), a post-hoc per-protocol analysis demonstrated a significant reduction (1.8 vs. 2.5 injections), suggesting a potential benefit in a more compliant patient group.
• ILUVIEN significantly extended the time to first supplemental therapy (185.4 days vs. 132.8 days), offering a less frequent treatment burden compared to the typical monthly or bi-monthly injections of anti-VEGF agents.
• Visual acuity and anatomical improvements were comparable between ILUVIEN and aflibercept, indicating similar efficacy in preserving vision and reducing macular edema.
• However, ILUVIEN showed a higher incidence of ocular adverse events, particularly cataracts (29.9% vs. 0.7% for aflibercept) and increased intraocular pressure (7.8% vs. 0.7% for aflibercept), which are known side effects of corticosteroid use and require careful management, potentially including laser or surgical interventions (4.5% vs. 1.3% for aflibercept).

Stakeholder Impact

• Shareholders may experience volatility due to the mixed clinical trial results, particularly the primary endpoint miss in the ITT population, which could impact future commercial prospects and stock valuation.
• Patients with early DME could benefit from ILUVIEN's extended duration of effect, potentially reducing the frequency of injections, but must weigh this against the higher risk of cataracts and increased intraocular pressure.
• Healthcare providers will need to carefully consider the trade-offs between ILUVIEN's less frequent dosing and its safety profile, especially the ocular side effects, when making treatment decisions for DME patients.

Key Dates

Recommendation

The recommendation is 'hold' because the clinical trial results present a complex picture. While the primary endpoint was not met in the Intent-to-Treat population, which is a significant negative for broad market perception and potential label expansion, the statistically significant benefit in the Per-Protocol population and the extended re-treatment interval offer a compelling value proposition for certain patient segments. However, the higher incidence of ocular adverse events, specifically cataracts and elevated intraocular pressure, introduces a notable risk. Investors should hold to assess how these mixed results are interpreted by the market, regulatory bodies, and the medical community, and to monitor the company's strategy for commercializing ILUVIEN given these findings.

Keywords

Diabetic Macular Edema, DME, ILUVIEN, Fluocinolone Acetonide, FAc, NEW DAY Study, Clinical Trial, Ophthalmology, Retinal Disease, Corticosteroids, Aflibercept, Anti-VEGF, SEC Filing, Pharmaceuticals